Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes

St. Luke's Hospital, Chesterfield, Missouri1 site in 1 country540 target enrollmentMarch 2015

ConditionsAtherosclerosis

InterventionsPolyarginine Vein soak treated with Lactated Ringers Solution

DrugsPolyarginine Vein soak treated with Lactated Ringers Solution

Overview

Phase: Phase 1
Intervention: Polyarginine
Conditions: Atherosclerosis
Sponsor: St. Luke's Hospital, Chesterfield, Missouri
Enrollment: 540
Locations: 1
Primary Endpoint: To study the effects of arginine on saphenous vein graft patency rates
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to study the effects of polyarginine treated vein grafts on graft patency for patients undergoing coronary artery bypass surgery.

Detailed Description

Double blind study with Lactated Ringers Solution and Lactated Ringers Solution with Arginine soaked for 10 minutes prior to grafting on the coronary arteries.

Registry

clinicaltrials.gov

Start Date

March 2015

End Date

November 2021

Last Updated

7 years ago

Study Type

Interventional

Study Design

Factorial

Sex

All

Investigators

Sponsor

St. Luke's Hospital, Chesterfield, Missouri

Responsible Party

Principal Investigator

Ron Fiehler

Biologically Modified Saphenous Vein Transplants for Improved CABG Outcomes

St. Luke's Hospital, Chesterfield, Missouri

Eligibility Criteria

Inclusion Criteria

•Subjects must be 25-95 years of age and able to give informed consent
•Use of an approved statin and anti-platelet medication for at least 24 months.
•Agreeable to Cardiovascular imaging at 12 months post-coronary artery bypass graft (CABG).
•First time coronary artery bypass surgery,redo coronary artery bypass surgery and combined valve repair/replacement surgery and coronary artery bypass graft surgery are eligible to participate in study.

Exclusion Criteria

•Acute traumatic injury, vasculitis or planned concurrent ventricular surgical restoration, automatic implantable cardioverter defibrillators (AICD) placement or valvular surgery.
•Hypercoaguable state.
•Comorbid illness making 2 year survival unlikely.
•Participation in another interventional investigative study of a cardiovascular drug or device within 30 days prior to CABG. May participate concurrently in other studies where the intervention/observation will not hinder execution of this study.
•Patients with any medical condition that, in the investigator's judgment, makes the patient ineligible or places the patient at undue risk (e.g. conditions that preclude standard invasive follow up procedures such as angiography, i.e. renal failure, bleeding diathesis or peripheral vascular disease preventing catheterization via the groin).
•Subject has clinical evidence of infection that the Investigator deems significant to the completion of the procedure or that could compromise the subject's safety.
•Any patient was has undergone more than 20 computerized tomography (CAT) scans.
•Any patient who is pregnant.